Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Deep brain stimulation

This article was originally published in The Gray Sheet

Executive Summary

Medtronic has filed a PMA for its deep brain stimulation therapy for patients with medically refractory epilepsy with partial-onset seizures. The application is supported by data from the randomized, double-blind Stimulation of the Anterior Nucleus of the Thalamus in Epilepy (SANTE) trial. Results presented in December at the American Epilepsy Society meeting showed that patients receiving DBS therapy in the left and right anterior nucleus of the thalamus, in conjunction with epilepsy medication, had significantly reduced seizure frequency compared to those receiving no stimulation (1"The Gray Sheet" Dec. 15, 2008). Medtronic has marketed the Activa DBS system for Parkinson's and essential tremor for more than 10 years

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT027672

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel